COVID-19 has propelled the importance of the health industry to astonishing heights. No longer confined to safeguarding the health and well-being of individuals, the sector is now providing the framework needed to restore the economic prosperity of entire countries. Consequently, the health industry has seen investment interest flock to the sector.
There has never been a better time to commercialise a health-related technology or innovation. However, it is a well-travelled and treacherous path. Some of the world's best innovations may never realise their full potential, unless they are fully backed by experts who can guide them every step of the way. Mawson specialises in helping institutions and businesses looking to commercialise health-related technologies.
HOW WE HELP
We have a proven track of success, leveraging a strong network of investors to successfully raise capital and develop commercialisation strategies.
And we work alongside our clients to deliver results.
Having a good idea is just the start. Investors look beyond the idea to understand who is tasked with "actualising" the strategy. Mawson assists with the following key challenges of commercialisation:
Raise capital from the right source that can add value to the investment.
Recruit key executives and the board.
Develop strategic plans.
Define the target market.
Oversee marketing initiatives.
Facilitate leadership team accountability framework.
Develop strategic alliances and JVs if applicable.
If you have breakthrough technology/innovation targeting the health sector, we'd like to hear from you. We can help you navigate through the complexities of commercialisation to deliver a fully scalable and profitable global product. Together, we hope to make a real difference to people's everyday lives.
We can help, please get in touch. We're happy to have an obligation free chat about how we could assist you.
Click here to contact us.
"It was Mawson’s input that showed us that there was a better way to get us to where we are today… we’ve been on a bit of a high since we’ve been associated with Mawson.”
Don McKenzie, Investor